Research on the drugs used to treat cancer and how well they work. Covers immunotherapy, chemotherapy-free regimens, biosimilars, targeted drugs, and treatment costs.
Researchers from China explore the mechanisms of action and clinical data of bispecific antibodies, which have shown promise in increasing cytotoxicity against cancerous cells and enhancing immune response towards tumor clearance. Several bsAbs are being evaluated in phase I-III clinical trials for lung cancer treatment.
Researchers developed a novel combination therapy that eradicates tumors in select patients, with prolonged survival rates. The therapy has shown promise in treating glioblastoma, a notoriously difficult-to-treat primary brain cancer.
A team of researchers is exploring the potential of HDAC inhibitors to treat sickle cell disease by reactivating the fetal hemoglobin gene. Early evidence suggests that panobinostat, a specific inhibitor, can increase fetal hemoglobin levels in red blood cells and mouse models.
The study shows that zolbetuximab delays tumor progression and improves overall survival by 25% compared to chemotherapy alone. Patients with CLDN18.2-positive tumors responded well to the treatment, indicating a new clinically relevant biomarker for gastric cancer.
A phase 2 clinical trial testing a treatment combining standard chemotherapy with azacitidine showed nearly 90% of patients with aggressive T-cell lymphoma achieved complete remission. The treatment, which targets gene-silencing marks on DNA, has an estimated two-year progression-free survival rate of 69.2%.
A multicentre registry study found that medicinal cannabis can safely relieve cancer pain while reducing the total number of medications and opioids taken. Products with an equal balance of THC and CBD were particularly effective in reducing pain intensity and symptoms.
Researchers have identified 11 somatic mutations in the RAS/MAPK pathway that contribute to treatment-resistant adult epilepsy, suggesting the potential for repurposed anti-cancer agents as new treatments. This study provides insight into the genetic mechanisms underlying this form of epilepsy and opens up new avenues for targeted ther...
Researchers at Cummings School of Veterinary Medicine and Tufts Medical Center have developed a new platform to test cardiac side effects of chemotherapy using canine heart tissue. The platform yields quicker and more comprehensive results than standard rodent models, making it a promising alternative for cancer drug toxicity testing.
Researchers at UCL have identified proteins in the blood associated with an increased risk of developing heart diseases, including heart failure. The findings could lead to more refined cancer treatments that minimize cardiotoxicity and improve survival rates.
Researchers found that spinal cord stimulation reduced pain response in rats with human lung cancer tissue without compromising paclitaxel effectiveness. The study also showed SCS improved antitumor efficacy of paclitaxel, providing evidence for its potential as a companion treatment.
Researchers identified copper's role in inflammation and found that it can trigger the expression of genes involved in cancer progression. They also developed a drug prototype called Supformin that blocks copper chemistry, reducing inflammation and cell transformation in cancer cells.
Researchers developed a biomarker signature test to predict which bladder cancer tumors will respond to immunotherapy, potentially improving survival rates. The study identified three types of responsive tumors and two non-responsive ones, providing insights into potential new treatments.
Scripps Research scientists develop a new strategy to identify small molecules that can alter protein function, offering a promising path for discovering targeted cancer drugs. By comparing how mirror image versions of small molecules impact clusters of proteins, they identified potential new drug targets such as MY-1B and EV-96.
Researchers at Stevens Institute of Technology have developed a drug delivery system using gold nanoparticles to target tumors with remarkable precision. The system reduces the potential for debilitating side effects by delivering drugs selectively to tumors, allowing for lower quantities and potentially life-saving treatments.
TRIO Pharmaceuticals is developing a proprietary platform of dual-action tumor immunity-enhancing drugs aimed at treating cancers with high unmet medical needs. The company's innovative approach selectively eliminates immunosuppressive cells, enhancing antitumor activity.
Researchers developed bottlebrush-like nanoparticles that deliver immunostimulatory drugs to tumors, provoking an immune response and slowing tumor growth. The approach avoids systemic inflammation, making it a potential solution for boosting immune system responses in cancer patients.
Researchers found that bad medical news can make patients more likely to choose brand name drugs over generics, resulting in increased healthcare expenditures. The study suggests that simply reminding patients of the equivalency of generic drugs via text message could improve their decision-making.
Researchers at The Mount Sinai Hospital have created versatile disease models of acute myeloid leukemia (AML), allowing for accurate study of the cancer's progression and response to drugs. These models, derived from induced pluripotent stem cells, can mimic different stages of AML and are nearly identical to those found in patients.
Researchers discuss rapamycin's potential to delay cancer onset by slowing cell proliferation and tumor progression. The mTOR pathway is involved in both cancer and aging, making rapamycin a promising chemopreventive agent.
Researchers discover loss of neurofibromin 1 (NF1) gene leads to resistance to alpelisib, a common treatment for advanced breast cancer. Dietary supplement N-acetylcysteine restores sensitivity to this treatment, offering new hope for improving treatment outcomes.
Researchers at Universitatsklinikum Bonn used CRISPR gene scissors to identify NAE1 as a driver of cisplatin resistance in testicular cancer. Inhibiting this protein with MLN4924 restores cisplatin's effectiveness and has an additional killing effect on tumor cells, offering new treatment options.
Enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may induce clinical activity against cancer throughout the body. The drug targets B7-H3 protein overexpressed on prostate cancer cells, blocking immune system inhibition and triggering tumor cell destruction by activating immune cells.
A team of scientists from City University of Hong Kong and HKUST discovered novel, tridimensional compounds with high anticancer activity and low toxicity. These compounds can overcome drug resistance in cancer cells by inducing a different cell death pathway.
Researchers at Rice University have created a new technology called PULSED that can deliver time-released drugs and vaccines for extended periods. The technology uses high-resolution 3D printing and soft lithography to produce microcylinders made of biodegradable polymers, which can be loaded with drugs and release them over time.
Researchers from Tokyo University of Science reveal the crystal structure of centromere-associated protein E (CENP-E), a promising target for inhibitor therapy. The discovery is expected to facilitate the development of anticancer drugs with fewer adverse effects on patients.
Researchers propose conjugating a cell-penetrating peptide to oxaliplatin to overcome chemotherapy resistance in colorectal cancer. The new approach reduces platinum accumulation in tumour microenvironment and healthy tissues.
Research analysis reveals gaps and uncertainties in evidence base for cancer drugs, including lack of relevance and inconsistent reporting. Findings emphasize the importance of improving communication of benefits and harms to support informed decision-making by patients and clinicians.
A new drug combination has doubled the expected time until cancer progression in heavily resistant head and neck cancer patients. The treatment, which includes a monoclonal antibody drug called ficlatuzumab, has shown an unusually high response rate of 38% in HPV-negative patients.
Researchers developed a 3D cell culture system to test fibroblast inhibitors with anti-cancer drugs. Combining nintedanib with cisplatin increased the latter's efficacy in suppressing cancer growth and invasion. The study provides a promising tool for preclinical drug testing.
Researchers from China have identified inosine as a potential broad-spectrum anti-inflammatory agent that improves survival in mice infected with SARS-CoV-2. The study also highlights TBK1 as a promising target for inhibiting cytokine storms and mitigating acute inflammatory lung injury.
The new medicine has shown promising results in a Phase 1 clinical trial, with 70% of patients stable after six weeks and one patient remaining stable for over two years. Developed by NTNU researcher Marit Otterlei, ATX-101 targets cancer cells' stress regulation system, leaving healthy cells unaffected.
A new study found that women with BRCA1 or BRCA2 mutations who are obese may experience higher rates of DNA damage in their breast tissue, which could contribute to breast cancer development. The researchers suggest that weight management and medications like metformin may be important for preventive care.
Researchers created a three-dimensional structure that mimics bone and houses osteosarcoma cells beside immune cells, finding increased inflammation reduces chemotherapy effectiveness. The study highlights the importance of the tumor microenvironment in disease progression and treatment.
Researchers at Mayo Clinic have made significant progress in treating multiple myeloma using chimeric antigen receptor therapy (CAR-T cell therapy), which has shown a median progression-free survival of 13.3 months compared to 4.4 months for standard treatment regimens.
Researchers have discovered how TKI cancer drugs cause inflammation, linking it to mitochondrial dysfunction and the NLRP3 inflammasome. The study found that all tested TKIs share a common off-target activity against mitochondrial SFKs.
Researchers at the Salk Institute discovered that combining two therapeutic drugs, entinostat and trametinib, can significantly reduce tumor volume and number in mice with LKB1-mutated non-small cell lung cancer. The findings could lead to clinical trials in humans and potentially transform treatment for cancers beyond NSCLC.
Researchers at Pusan National University have developed a novel FRET-based biosensor to detect double-strand breaks in DNA, providing real-time information on γH2AX. The sensor's sensitivity is higher than conventional immunostaining techniques, making it useful for identifying DNA damage factors and elucidating repair mechanisms.
A new review paper suggests that selective protection of normal cells from chemotherapy could increase the therapeutic window and improve outcomes for cancer patients. The authors propose using antagonistic drug combinations to kill drug-resistant cancer cells, reducing side effects and improving quality of life.
Researchers have developed a novel 3D covalent organic framework, TUS-64, with the largest pore size and lowest density ever recorded. The material shows promise as a drug nanocarrier vehicle, with high capacity to hold drugs and sustained release rate.
A new drug called CADD522 blocks a gene associated with driving bone cancer's spread, increasing survival rates by 50% in mice implanted with human bone cancer. The breakthrough treatment shows promise in all main bone cancer subtypes and has the potential to save lives and reduce disability.
A team of scientists has developed a novel, implantable drug delivery system that can be controlled by external light sources and is absorbable by the body. This technology has promising implications for treating various medical conditions, including pain management and cancer treatment.
The NCCN Annual Conference will debut a new hybrid format featuring in-person events at a new venue, allowing for hallway conversations and networking opportunities. The conference will also showcase more than 100 abstract poster presentations on various oncology-related categories.
Patients with stage IIIB-IV melanoma who received neoadjuvant pembrolizumab had a significantly lower risk of cancer recurrence compared to those receiving adjuvant therapy only. The study found improved event-free survival rates in the neoadjuvant group, suggesting that starting immunotherapy before surgery generates better outcomes.
Applying evolutionary principles to medicine inspires new ways of preventing and treating disease, including overcoming chemotherapy resistance and antibiotic resistance. Evolutionary-inspired strategies like 'anti-evolution' drugs and extinction therapy can tackle these global health threats.
Researchers at the Paul Scherrer Institute have developed a film that demonstrates the potential of photopharmacology in treating diseases such as cancer. The new approach uses light to switch on and off a molecular photoswitch, allowing for targeted and reversible drug action.
Researchers discovered that combining ferroptosis induction with immune checkpoint inhibition reduces liver tumour growth and metastases, offering a promising new approach for treating liver cancer
Researchers at University of Gothenburg developed AI method using graph theory and neural networks to analyze cell movement, enabling better understanding of biological processes and development of new medical technologies. The method can reconstruct cell paths and test medication effectiveness as potential cancer treatments.
Researchers found that gatekeeper mutations in kinases can destabilize the inactive form, making them more active and prone to cancer recurrence. This could inform which drugs oncologists use as a first-line treatment.
Researchers at Harvard's Wyss Institute developed a method to fine-tune CAR-T cell stimulation using artificial antigen-presenting scaffolds. This approach enhances consistency and potency of resulting CAR-T cell products, allowing for better cancer treatment outcomes.
A study published in the Journal of Urology found that using Mark Cuban's cost-plus drug pricing model could save Medicare an estimated $1.29 billion annually on urological drugs. This would lead to more affordable treatment options for patients and redirect taxpayer funds towards other important issues.
The NCI is funding a $587,000 research grant to improve KRAS treatment resistance in pancreatic cancer. Dr. Andrew Waters aims to develop personalized medicine approaches by studying unique resistance mechanisms.
A new study reveals that the immune system mounts a weak response to lung cancer due to an environment created by bacteria in the lymph nodes near the lungs. T-cell responses are suppressed by regulatory T cells and interferon gamma produced in response to commensal bacterial presence.
Researchers report an updated analysis from a phase I study of mivavotinib, a spleen tyrosine kinase inhibitor, in patients with relapsed/refractory B-cell lymphoma. The study showed a 45% overall response rate and median duration of response of 28.1 months in the overall cohort.
A study found that immune checkpoint inhibitors enhance chemotherapy-induced neuropathic pain by blocking interaction between macrophages and neurons via PD1-PDL1 synergy. This discovery could lead to the development of therapeutic alternatives to prevent pain while maintaining anti-neoplastic effects.
A research team led by Professor Kwang-Hyun Cho at KAIST has developed a fundamental technology to revert metastatic lung cancer cells to a non-metastatic state. This breakthrough could lead to the elimination of drug resistance and metastatic potential in cancer cells, while increasing their responsiveness to chemotherapy.
Scientists at MIT have designed a novel nanoparticle platform that can deliver optimal ratios of multiple cancer drugs, leading to enhanced efficacy and reduced side effects. The bottlebrush-shaped particles can be loaded with varying concentrations of drugs, enabling the precise delivery of synergistic combinations.
A study found a link between pain and indigestion medication purchases and ovarian cancer diagnoses, suggesting earlier symptom recognition. The research suggests that loyalty card data can be used to identify potential ovarian cancer cases.
Researchers seek to reduce medical errors among patients with limited English proficiency by implementing three different translation approaches. The goal is to compare the effectiveness of telephone interpreter-based and in-person interpreter-assisted communication in reducing errors.
Researchers found that female patients with diffuse large B-cell lymphoma treated in the afternoon had reduced mortality rates and cancer recurrence compared to those treated in the morning. The study suggests that timing chemotherapy delivery according to an individual's circadian clock may improve treatment outcomes.
A new study finds that andiroba oil accelerates wound healing, increases contraction rates, and promotes local re-epithelialization. The oil also presents a similar potential to low-level laser therapy (LLLT) in treating oral mucositis, a common side effect of chemotherapy.